ACS Medicinal Chemistry Letters · 2023 · 21 citations · 20 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationAllosteric Drug DesignAllosteric RegulationEnzyme InhibitionPotency OptimizationTyrosine Kinase InhibitorsAllosteric Drug DiscoveryAllosteric DrugsAllosteric Kinase InhibitorsAllosteric Ligand DiscoveryFused Heterocyclic SystemsProtein Tyrosine Phosphatase InhibitorsScaffold Exploration
Protein tyrosine phosphatase SHP2 is an oncogenic protein that can regulate different cytokine receptor and receptor tyrosine kinase signaling pathways. We report here the identification of a novel series of SHP2 allosteric inhibitors having an imidazopyrazine 6,5-fused heterocyclic system as the central scaffold that displays good potency in enzymatic and cellular assays. SAR studies led to the identification of compound 8, a highly potent SHP2 allosteric inhibitor. X-ray studies showed novel stabilizing interactions with respect to known SHP2 inhibitors. Subsequent optimization allowed us to identify analogue 10, which possesses excellent potency and a promising PK profile in rodents.
20
Crystal Structure of the Tyrosine Phosphatase SHP-2
Peter Hof, Scott Pluskey, Sirano Dhe‐Paganon et al. · Cell · 1998 · 1K citations · Full text
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen, Matthew J. LaMarche, Ho Man Chan et al. · Nature · 2016 · 929 citations
Mohamed Bentires‐Alj, J. Guillermo Paez, Frank David et al. · Cancer Research · 2004 · 513 citations · Full text